⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 1, 2024Open Access

Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors

Hyung‐Don Kim Min‐Hee Ryu Young Soo Park Changhoon Yoo Sung Joo Kim Yoon‐Koo Kang

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure S3 Supplementary Figure S4 Supplementary Figure S5

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2024) studied this question.

synapsesocial.com/papers/68e62195b6db6435875b37bb https://doi.org/10.1158/1078-0432.26134159.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors2024
2Supplementary Data1 from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor2025
3Data from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors2024
4Supplementary Figure S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)2025
5Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)2025